Spero Therapeutics Reports Q2 2026 Earnings with $9.6M Net Loss and Secures $105M Financing
In its second-quarter earnings report for 2026, Spero Therapeutics (SPRO) reported zero revenue due to the prior realization of collaboration income from Pfizer and GSK. The company posted a net loss of $9.6 million compared to $1.7 million in Q2 2025, with diluted net loss per share at $0.16 versus $0.03 previously. Research and development expenses dropped significantly due to the early completion of its Utebzi Phase III trial, while general and administrative costs rose from increased business development activities. Spero announced a $105 million nonrecourse royalty financing with Healthcare Royalty backed by future GSK payments for Utebzi, which was FDA-approved in June 2026 as the first oral carbapenem for complicated urinary tract infections. The company now plans to focus on immune-mediated diseases and is advancing SP001, an immunology candidate licensed from Innovent Biologics. Spero expects its current capital resources—including proceeds from recent financing—to fund operations through mid-2029.
Tickers: $PFE
Topics: cash runway expenses financing net loss revenue